Loncastuximab tesirine-lpyl

(Zynlonta®)

Loncastuximab tesirine-lpyl

Drug updated on 10/25/2024

Dosage FormInjection (intravenous; 10 mg)
Drug ClassCD19-directed antibodies and alkylating agent conjugates
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • In the ASCT-eligible group, the 1-year progression-free survival (PFS) rate for CAR T-cell therapy was 0.40 (95% CI (Confidence interval), 0.15 to 0.65), while for chemotherapy followed by ASCT, it was 0.34 (95% CI, 0.30 to 0.37). There was no significant difference in effectiveness between these two treatments.
  • In the ASCT-ineligible group, CAR T-cell therapy had a 1-year PFS rate of 0.40 (95% CI, 0.35 to 0.46), while the tafasitamab group showed a 1-year PFS rate of 0.47 (95% CI, 0.37 to 0.57). CAR T-cell therapy demonstrated better outcomes than chemotherapy and therapies involving ibrutinib, lenalidomide, and selinexor. However, there was no significant difference in effectiveness between CAR T-cell therapy and loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group.
  • The study does not provide specific safety information regarding loncastuximab tesirine-lpyl (Zynlonta) or the other drugs mentioned. Therefore, no detailed safety outcomes are available for synthesis in this section.
  • The study examined two key groups: ASCT-eligible and ASCT-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). In the ASCT-eligible group, CAR T-cell therapy and chemotherapy followed by ASCT showed no significant difference in 1-year progression-free survival (PFS). In the ASCT-ineligible group, CAR T-cell therapy demonstrated significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor, but was comparable in effectiveness to loncastuximab, polatuzumab plus bendamustine and rituximab, and tafasitamab.

Product Monograph / Prescribing Information

Document TitleYearSource
Zynlonta (loncastuximab tesirine-lpyl) Prescribing Information.2022ADC Therapeutics SA, Epalinges, Switzerland

Systematic Reviews / Meta-Analyses